最新一期业绩显示，2025年一季报，公司实现营业收入6584.61万元，同比9.34%；净利润1318.67万 元，同比16.16%，销售毛利率58.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13天臣医疗55.8957.865.2530.03亿行业平均 54.7951.294.80116.92亿行业中值37.8638.002.7755.22亿1九安医疗11.1511.280.88188.19亿2英科医疗 15.9217.161.42251.53亿3新华医疗16.1314.951.32103.38亿4振德医疗16.1915.261.0358.78亿5山东药玻 16.2416.291.87153.63亿6奥美医疗16.7216.391.7260.41亿7康德莱17.6917.711.4738.13亿8维力医疗 17.7518.972.2341.62亿9九强生物17.8316.582.1888.30亿10奥泰生物18.5619.571.5059.18亿11鱼跃医疗 20.0419.652.71354.88亿12三鑫医疗20.2720.283.3446.13亿 来源：金融界 8月7日，天臣医疗今 ...

Core Viewpoint - Tianchen Medical (688013) experienced a decline in stock price, closing at 37.88 yuan on August 6, 2025, down 4.51% from the previous day, indicating a negative trend in investor sentiment and market performance [1]. Group 1: Stock Performance and Trading Data - On August 6, 2025, the stock had a turnover rate of 7.1%, with a trading volume of 57,600 hands and a total transaction value of 215 million yuan [1]. - The net outflow of main funds was 15.8863 million yuan, accounting for 7.41% of the total transaction value, while retail investors saw a net inflow of 5.1648 million yuan, representing 2.41% of the total [1]. - Over the past five days, the stock has shown fluctuating performance, with a notable drop on August 6, following a slight increase on August 4 [1][2]. Group 2: Financing and Margin Trading - As of August 6, 2025, the financing balance was 102 million yuan, with a net financing purchase of 12.9725 million yuan, indicating positive investor interest in leveraging positions [2]. - The margin trading data shows no short selling activity, with a total margin trading balance of 102 million yuan [2]. Group 3: Company Financials and Industry Comparison - Tianchen Medical reported a total market capitalization of 3.074 billion yuan, significantly lower than the industry average of 11.525 billion yuan, ranking 101 out of 123 in the medical device sector [4]. - The company’s net profit for the first quarter of 2025 was 13.1867 million yuan, reflecting a year-on-year increase of 16.16%, while its main revenue was 65.8461 million yuan, up 9.34% year-on-year [4]. - The company has a gross margin of 58.46%, which is higher than the industry average of 51.31%, indicating strong operational efficiency [4].

8月4日，沪深两融数据显示，天臣医疗获融资买入额0.11亿元，居两市第1112位，当日融资偿还额0.13 亿元，净卖出169.97万元。 最近三个交易日，31日-4日，天臣医疗分别获融资买入0.10亿元、0.08亿元、0.11亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tianchen Medical, which closed at 39.98 yuan, marking a 3.28% increase, with a rolling PE ratio of 60.39, the lowest in 1139 days, and a total market value of 3.245 billion yuan [1][2] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, positioning Tianchen Medical at the 89th rank within the industry [1][2] - As of March 31, 2025, Tianchen Medical has 4,443 shareholders, an increase of 68 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tianchen Medical focuses on the research, innovation, production, and sales of high-end surgical staplers, with key products including endoscopic staplers, tubular staplers, linear cutting staplers, pouch staplers, and linear suturing staplers [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, up 16.16%, with a gross profit margin of 58.46% [1]

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance, with a recent closing price of 38.71 yuan, reflecting a 4.85% increase from the previous week, and reaching a near one-year high of 39.0 yuan during trading [1] Company Announcements - As of July 31, 2025, Tianchen Medical has repurchased a total of 2,505,324 shares, with a total expenditure of approximately 42.5 million yuan [1] - The company announced a share repurchase plan on December 27, 2023, with a total repurchase amount set between 18 million and 36 million yuan, at a maximum price of 30 yuan per share, over a 12-month period [1] - The repurchase amount was subsequently increased to between 36 million and 72 million yuan on July 9, 2024, and further adjusted to between 46 million and 80 million yuan on December 25, 2024, with the repurchase period extended to December 26, 2025 [1] - On January 6, 2025, the source of funds for the repurchase was adjusted to include the company's own funds and a special loan from CITIC Bank, not exceeding 34.65 million yuan [1] - The highest repurchase price recorded was 21 yuan per share, while the lowest was 11.87 yuan per share [1]

Group 1 - The company approved a share repurchase plan with a total fund amount not less than RMB 18 million and not exceeding RMB 36 million, with a repurchase price cap of RMB 30.00 per share, valid for 12 months from the board's approval date [2] - The company later increased the repurchase fund amount to not less than RMB 36 million and not exceeding RMB 72 million, maintaining other aspects of the repurchase plan unchanged [3] - The company further adjusted the repurchase fund amount to not less than RMB 46 million and not exceeding RMB 80 million, extending the repurchase period by another 12 months until December 26, 2025 [4] Group 2 - The company modified the source of repurchase funds to include self-owned funds and a special loan from CITIC Bank, with the loan amount not exceeding RMB 34.65 million [5] - As of July 31, 2025, the company had repurchased a total of 2,505,324 shares, accounting for 3.09% of the total share capital, with a total payment of approximately RMB 42.5 million [6] - The company will adhere to relevant regulations and timely disclose information regarding the share repurchase progress [6]

Group 1 - The company Tianchen Medical announced that it did not conduct any repurchase transactions in July 2025 [2]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-047 天臣国际医疗科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 回购方案首次披露日 2023/12/28，由董事长、控股股东及实际控制人之 一陈望宇先生提议 回购方案实施期限 2023 年 12 月 27 日~2025 年 12 月 26 日 预计回购金额 4,600万元~8,000万元 回购用途 □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 2,505,324股 累计已回购股数占总股本比例 3.09% 累计已回购金额 4,249.89万元 实际回购价格区间 11.87元/股~21.00元/股 重要内容提示： 一、回购股份的基本情况 天臣国际医疗科技股份有限公司（以下简称"公司"）于 2023 年 12 月 27 日召 开第二届董事会第十次会议，审议通过了《关于<公司以集中竞价交易方式回购公 司股份的方案>的议案》，同意公司以集中竞价交易方式回购公司股份， ...

格隆汇8月1日丨天臣医疗(688013.SH)公布，2025年7月，公司未进行回购交易。截至2025年7月31日， 公司已累计回购公司股份2,505,324股，占公司总股本的比例为3.09%，回购成交的最高价为21.00元/ 股、最低价为11.87元/股，支付的资金总额约为人民币4,249.89万元（不含印花税、交易佣金等交易费 用）。 ...

Group 1 - The company announced a share repurchase plan to be implemented from December 27, 2023, to December 26, 2025 [1] - As of July 31, 2025, the company has repurchased a total of 2.5053 million shares, accounting for 3.09% of the total share capital [1] - The repurchase price ranged from 11.87 yuan to 21 yuan per share, with a total expenditure of approximately 42.4989 million yuan [1] Group 2 - The total amount allocated for the repurchase is expected to be between 46 million yuan and 80 million yuan [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]